Ophthalmologica Update: The Peer-reviewed Journal Of EURETINA Edited By Sebastian Woolf

Volume: 238 Issue: 4

Ophthalmologica Update: The Peer-reviewed Journal Of EURETINA Edited By Sebastian Woolf
Sebastian Wolf
Published: Wednesday, November 1, 2017
NEW CATETHER PROVIDES SAFE AND EFFECTIVE RETINAL FLUID DRAINAGE External drainage of subretinal fluid (SRF) using a 24-G Optiva IV catheter is safe, efficient and useful in eyes with bullous exudative retinal detachment (RD), new research suggests. In a study involving 13 eyes of 13 patients with bullous exudative RD, SRF drainage was successfully accomplished in all eyes using a transconjunctival scleral incision with the 24-G catheter. Except for one case of localised subretinal haemorrhage, no complications were noted. J Peng et al, “A Modified Technique for the Transconjunctival and Sutureless External Drainage of Subretinal Fluid in Bullous Exudative Retinal Detachment Using a 24-G i.v. Catheter”, Ophthalmologica 2017, Volume 238, Issue 4. THREE-INJECTION LOADING DOSE EXTENDS TREATMENT-FREE INTERVAL In a study involving 61 eyes of 56 patients with myopic choroidal neovascularisation, eyes on a pro re nata (PRN) ranibizumab regimen appeared to achieve about the same visual outcomes whether they received a loading dose of three consecutive monthly injections or a loading dose of just one injection (p= 0.824). However, after a mean follow-up of 53 months, eyes that received the three-injection loading dose had a significantly longer treatment-free interval than those that received the one-injection loading dose (36.9 months vs 19.2 months; p < 0.001). 
C Calvo-González et al, “Long-Term Outcomes of Two Different Initial Dosing Regimens of Intravitreal Ranibizumab Used to Treat Myopic Choroidal Neovascularization”, Ophthalmologica 2017, Volume 238, Issue 4. EARLY DETECTION AND TREATMENT ACHIEVES BETTER LONG-TERM RESULTS IN NEOVASCULAR AMD Eyes with neovascular AMD treated early in the course of their disease appear to remain responsive to anti-VEGF therapy longer than those with more advanced disease at the time treatment is initiated, according to the findings of a retrospective review study. It showed that among 67 eyes consecutively treated with more than 30 intravitreal anti-VEGF injections between 2007 and 2014, those with good final visual acuity also had better initial VA (p = 0.020) and maintained it. In contrast, patients with moderate-to-poor final VA improved significantly after the first three monthly injections, and thereafter deteriorated consistently, mostly during the third (p = 0.019) and fourth (p = 0.006) years. Patients with initially moderate-to-poor vision also had more scarring and intraretinal fluid. O.Sagiv et all, “Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections”, Ophthalmologica 2017, Volume 238, Issue 4.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!

ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.

Read more...

ESCRS Today 2025: A Congress for Everyone

From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.

Read more...

ESCRS Today 2025: All Eyes on Innovation

Watching out for obstacles and opportunities

Read more...

Beyond the Numbers

Empowering patient participation fosters continuous innovation in cataract surgery.

Read more...

Thinking Beyond the Surgery Room

Practice management workshop focuses on financial operations and AI business applications.

Read more...

Aid Cuts Threaten Global Eye Care Progress

USAID closure leads retreat in development assistance.

Read more...

Supplement: ESCRS Clinical Trends Series: Presbyopia

Read more...

Debate: FS-LASIK or KLEx for Hyperopia?

FS-LASIK has more of a track record, but KLEx offers advantages.

Read more...

Four AI Applications Ready for Practice

Commercial offerings may save time, improve practice and research.

Read more...

Perioperative Medication Regimens for Cataract Surgery

Randomised controlled clinical trial results provide evidence-based guidance.

Read more...